Bazedoxifene

Bazedoxifene
Clinical data
Trade names	Conbriza, Duavee, Duavive, Viviant
Other names	TSE-424; WAY-140424; WAY-TSE-424
AHFS/Drugs.com	International Drug Names
License data	EU EMA: by INN;
Routes of; administration	By mouth
ATC code	G03XC02 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 1-[4-[2-(azepan-1-yl)ethoxy]benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol;
CAS Number	198481-32-2 ;
PubChem CID	154257;
IUPHAR/BPS	7355;
DrugBank	DB06401 ;
ChemSpider	135921 ;
UNII	Q16TT9C5BK;
ChEMBL	ChEMBL46740 ;
PDB ligand	29S (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID70173593 ;
ECHA InfoCard	100.232.728
Chemical and physical data
Formula	C30H34N2O3
Molar mass	470.613 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1ccc(cc1)c3c(c2cc(O)ccc2n3Cc5ccc(OCCN4CCCCCC4)cc5)C;
	InChI InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3 ; Key:UCJGJABZCDBEDK-UHFFFAOYSA-N ;
	(what is this?) (verify)

Bazedoxifene, used as bazedoxifene acetate, is a medication for bone problems and possibly (pending more study) for cancer.^[1] It is a third-generation selective estrogen receptor modulator (SERM).^[2] Since late 2013 it has had U.S. FDA approval for bazedoxifene as part of the combination drug Duavee in the prevention (not treatment) of postmenopausal osteoporosis. It is also being studied for possible treatment of breast cancer and pancreatic cancer.^[3]